title: In that case: your company has invested heavily in developing an AIDS vaccine and wishes to embark on clinical trials. Commentary.
authors.affiliation: Bioethics Centre, University of Otago, New Zealand.
authors.forename: D
authors.initials: D
authors.lastname: Evans
mesh_terms: D016915:AIDS Vaccines; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D017954:Africa South of the Sahara; D002986:Clinical Trials as Topic / Q000941:ethics* / Q000592:standards*; D019049:Developed Countries; D003906:Developing Countries; D026724:Ethical Review / Q000592:standards*; D006801:Humans; D038622:Internationality; D009042:Motivation; D035842:Research Subjects; D018570:Risk Assessment
chemical_list: D016915:AIDS Vaccines